Neuroscience

Findings from pivotal nipocalimab Phase 3 study in a broad antibody positive population of people living with generalized myasthenia gravis (gMG) published in The Lancet Neurology

January 23, 2025

Neuroscience

SPRAVATO® (esketamine) approved in the U.S. as the first and only monotherapy for adults with treatment-resistant depression

January 21, 2025

Neuroscience

Johnson & Johnson’s Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer’s Disease

January 8, 2025

Neuroscience

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

October 24, 2024

Neuroscience

Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study

First FcRn blocker to demonstrate sustained disease control over 24 weeks in antibody positive adolescents aged 12 – 17 years, broadening the population in which nipocalimab has been studied

October 15, 2024

Neuroscience

Johnson & Johnson showcases innovation and commitment to people living with gMG, presenting 25 abstracts at AANEM Annual Meeting and MGFA Scientific Session

October 3, 2024

Neuroscience

Janssen to Highlight Latest Research from Nipocalimab Clinical Development Program to Address Unmet Need in Myasthenia Gravis at AANEM 2023 Meeting

October 16, 2023

Neuroscience

Janssen to Showcase New Insights and Commitment to Accelerating Hope and Healing for Serious Mental Illness at Psych Congress 2023

September 6, 2023

Search Results

No Results

Recently Viewed

Neuroscience latest news